The strength of the regulatory system set up by the Prescription Drug User Fee Act (PDUFA) and its reauthorizations has been highlighted by the US FDA’s strong and consistent performance on review metrics during the disruptions of a historic disease outbreak.
The FDA’s Center for Drug Evaluation and Research cleared 27 new molecular entity and novel biologic approvals in the first...





